Researchers reported that an optimized VH domain-based anti–fibroblast activation protein (FAP) CAR-T design showed enhanced antitumor persistence and improved preclinical safety compared with a benchmark construct, in reported preclinical testing. The work focused on redesigning the receptor elements to improve performance without introducing new toxicity signals. The result supports continued investment in next-generation CAR-T engineering for solid tumors, where persistence and controlled activity remain core barriers to translation. While still preclinical, the comparative benchmark approach provides a clearer yardstick for how specific CAR design changes translate into functional duration in tumor models.